Skip to main content
OpenTrials
Completed

NCT Number: NCT02678169

European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke

Prospective, single-arm, multicenter, observational registry of the ACE Reperfusion Catheters and the Penumbra System in Europe. Consecutive patients presenting within 6 hours from symptom onset with an acute ischemic stroke (within the internal carotid artery and internal carotid terminus, middle cerebral - M1/M2 segments) due to anterior circulation large vessel occlusion (LVO) will be treated using the ADAPT technique with thrombo-aspiration as first intention and site routine practice.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Universitätsklinikum Schleswig-Holstein

Lübeck, 23538, Germany

About this study

Prospective, single-arm, multicenter, observational registry of the ACE Reperfusion Catheters and the Penumbra System in Europe. Consecutive patients presenting within 6 hours from symptom onset with an acute ischemic stroke (within the internal carotid artery and internal carotid terminus, middle cerebral - M1/M2 segments) due to anterior circulation large vessel occlusion (LVO) will be treated using the ADAPT technique with thrombo-aspiration as first intention and site routine practice.

The follow-up visit will occur 24 hours, 7-10 days or discharge, 30 days and 90 days post-procedure and will review patient's functional outcome, quality of life, and adverse events.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • General inclusion criteria:
  • From 18 years of age
  • Present with symptoms consistent with an acute ischemic stroke within 6 hours of stroke symptom onset
  • Arterial occlusion of the distal intracranial carotid artery (ICA and ICA terminus) or middle cerebral artery (M1/M2)
  • National Institute of Health Stroke Scale (NIHSS) ≥ 2
  • Signed Informed Consent Form.

Imaging inclusion criteria:

  • CT ASPECT score from 6 to 10 (>6) or according to MR DWI ASPECT score from 5 to 10 (>5).

Exclusion criteria

  • General exclusion criteria:
  • Associated myocardial infarction or severe infection (endocarditis or sepsis)
  • Laboratory evidence of coagulation abnormalities, with an International Normalized Ratio (INR) of > 3.0 or platelets count < 40 x109/L or APTT > 50 sec
  • Uncontrolled hypertension (defined as systolic blood pressure > 185 mmHg or diastolic blood pressure > 110 mmHg)
  • Baseline glucose < 2.7 or > 22.2 mmol/L
  • Pre-stroke mRS score > 2
  • Seizure at the onset of stroke
  • Arterial tortuosity that would prevent the device from reaching the target vessel
  • Time of stroke symptoms onset unknown
  • Life expectancy less than 90 days prior to stroke onset
  • Females who are pregnant or lactating
  • Known serious sensitivity to radiographic contrast media.

Imaging exclusion criteria:

  • CT/MRI evidence of the following conditions at screening:
  • Significant mass effect with midline shift
  • Evidence of intracranial hemorrhage (ICH), aneurysm, or arteriovenous malformation (AVM)
  • Angiographic evidence of tandem extracranial occlusion or an arterial stenosis proximal to the occlusion that requires treatment prior to thrombus removal. Moderate stenosis not requiring treatment is not an exclusion criterion.
  • Angiographic evidence of preexisting arterial injury, such as carotid dissection, complete cervical carotid occlusion, or vasculitis.

Treatment and study plan

Penumbra Aspiration System

Device

Penumbra Aspiration System using the ADAPT technique for recanalization of an occlusion large vessel in the brain

Primary outcomes

  1. Angiographic revascularization of the occluded target vessel at immediate post-procedure as defined by a TICI 2b or 3 score.

    Time frame: Immediate post-procedure

  2. Functional patient outcome at 90 days post-procedure as defined by a modified Rankin Score (mRS) 0-2.

    Time frame: 90 days post-procedure

Secondary outcomes

  1. Incidence of device and procedure related Serious Adverse Events (SAEs) at 24 hours and 30 days from stroke treatment

    Time frame: 24 hours and 30 days from stroke treatment

  2. All causes of mortality and morbidity at 90 days

    Time frame: 90 days

  3. Occurrence of embolization in previously uninvolved (or new) territories (ENT) as seen on the final control angiogram at the end of procedure

    Time frame: At the end of interventional surgical procedure

  4. Occurrence of symptomatic intracranial hemorrhages (sICH) at 24 hours

    Time frame: 24 hours

  5. Occurrence of vessel damages at the end of the ADAPT procedure.

    Time frame: At the end of the interventional surgical procedure

  6. NIHSS score at 7-10 days post-procedure.

    Time frame: 7-10 days post-procedure

  7. Times to revascularization

    Time frame: From symptom onset to various times during the interventional surgical procedure

    • From symptom onset to CT-scan/MRI at the institution
    • From CT-scan/MRI at the institution to groin access
    • From groin puncture to final revascularization result.
  8. Quality of Life: EQ-5D 3L score at 90 days compared to the one at 7-10 days post-procedure.

    Time frame: 90 days

  9. Heath Economics: Total duration of hospitalization with related healthcare resources

    Time frame: Average time frame 3-7 days.

    • Health care professionals encountered/consulted before/after intervention
    • Tests performed before/after intervention.

Sponsors and collaborators

Lead sponsor

Penumbra Inc.

Industry

Registry information

Official study title

A Prospective, Multicenter, Observational, Single-arm European Registry on the ACE Reperfusion Catheters and the Penumbra System in the Treatment of Acute Ischemic Stroke

Acronym: PROMISE

Important dates

Study start
2016
Primary completion
2017
Study completion
2017
First posted
Feb 9, 2016
Registry last updated
Jan 17, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.